Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...
US FDA Approves Updated COVID-19 mRNA Vaccines from Pfizer/BioNTech and Moderna Ahead of Winter
The U.S. Food and Drug Administration (FDA) has granted approval to two updated mRNA COVID-19...
Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals
Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange...
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and...
Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma
Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...
China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments
The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State...
Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments
Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...
Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...
Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE
Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...
ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...
Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease
Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301...
Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy
Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...
Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...
Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis
Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...
Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA
Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...
Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...
UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...